Ticker HubNasdaq

PRTA

Prothena Corporation plc Ordinary Shares

PHARMACEUTICAL PREPARATIONS

Latest price

$8.47-4.62%

As of Oct 30, 2026, 4:01 PM EDT · Market data by Massive

Market cap

$455.9M

Volume

452.3K

Previous close

$8.88

Day range

$8.35 – $8.90

Listed

Dec 18, 2012

Coverage

1 article

Price performance

Recent trading

5 trading days · 15-minute intervals · ET

Five-day open $8.25Latest interval $8.47

Newsroom

Latest PRTA coverage

BreakingNewsOct 19, 2023

Prothena Corporation: The Next BIG Thing In The Alzheimer’s Battle Is Up For Sale!

Reports suggest that Prothena might be contemplating strategic alternatives including a potential sale that could forever change the game in the battle against Alzheimer's disease.

PRTA

Company overview

Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.

Industry: PHARMACEUTICAL PREPARATIONS
Employees: 67
Headquarters: DUBLIN 2, L2
CIK: 0001559053

Company website View advanced chart

SEC filings

PRIMARY DOCUMENT

8-K

PRIMARY DOCUMENT

8-K

PRIMARY DOCUMENT

Browse EDGAR

Profile at a glance

Dec 18, 2012

Listed

Employees

Market data may be delayed and is provided for informational purposes only. SmallCapsDaily content is not investment advice.